Old Web
English
Sign In
Acemap
>
Paper
>
1542PSafety of lorlatinib in subgroups of patients from a phase I/II trial
1542PSafety of lorlatinib in subgroups of patients from a phase I/II trial
2019
Eudald Felip
Ben Solomon
Benjamin Besse
Todd Michael Bauer
Ross A. Soo
D.R. Camidge
Rita Chiari
Alessandra Bearz
C. C. Lin
Shirish M. Gadgeel
Eng-Huat Tan
Takashi Seto
Geoffrey R. Oxnard
Gerson Peltz
Antonello Abbattista
Holger Thurm
Francesca Toffalorio
S-H.I. Ou
Alice T. Shaw
Keywords:
Pharmacy (field)
Visual accommodation
General surgery
Adverse effect
Internal medicine
Lorlatinib
Medicine
Extremity Pain
multiple dose regimen
phase i ii
racial group
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]